Isomorphic Labs raises 2.1 billion dollars for AI drug work
Isomorphic Labs has secured 2.1 billion dollars in a funding round led by Thrive Capital to expand its AI-driven drug design engine. The Alphabet spin-off plans to launch its first clinical trials by late 2026 as it works to accelerate medical research and development timelines.
Xurve View
Insights:
Xurve View
Isomorphic Labs raised $2.1 billion in a funding round led by Thrive Capital to scale its artificial intelligence-driven drug discovery platform. The round included existing backers Alphabet and Google Ventures alongside new investors MGX, Temasek, and CapitalG (a new backer). This capital injection supports a broader industry push to use AI for shortening drug development timelines and reducing research costs.
